Improved Transparency In Europe: TTIP And Trade Secrets Legislation Could Hold Back Progress In 2015
Castigated for not providing public access to clinical trial data nor details of a proposed free trade deal with the U.S., the European Commission and national regulatory agencies will push transparency this year. But pending legislation on trade secrets, data protection and trademarks could hold back progress in this arena.
You may also be interested in...
Andreas Pott, who helped steer agency through Mediator scandal, becomes acting director again as irregularities in 2011’s recruitment process force departure of Guido Rasi – who himself might still get top job again once hiring process reboots.
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.